3D Medicines Inc
01244
Company Profile
Business description
3D Medicines Inc is a commercial-stage biopharmaceutical company engaged in the research and development of oncology therapies for cancer patients, especially those who require long-term care. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.
Contact
No. 3 and No. 5, Laiyang Road
Shandong
Qingdao
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
183
Stocks News & Analysis
stocks
The ‘other’ AI chip behemoth that might just be getting started
The magnitude of growth at Broadcom continues to astound us.
stocks
Why ANZ changes aren’t just about cutting costs
The banking major needs to prevent key product offerings from falling further behind the competition.
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,095.20 | 28.80 | 0.32% |
| CAC 40 | 7,761.32 | 11.93 | 0.15% |
| DAX 40 | 23,632.95 | 85.50 | -0.36% |
| Dow JONES (US) | 45,468.52 | 242.82 | -0.53% |
| FTSE 100 | 9,225.39 | 17.14 | -0.19% |
| HKSE | 26,200.26 | 262.13 | 1.01% |
| NASDAQ | 21,916.08 | 36.59 | 0.17% |
| Nikkei 225 | 43,837.67 | 378.38 | 0.87% |
| NZX 50 Index | 13,276.24 | 22.51 | 0.17% |
| S&P 500 | 6,534.73 | 22.12 | 0.34% |
| S&P/ASX 200 | 8,830.40 | 40.00 | 0.46% |
| SSE Composite Index | 3,812.22 | 4.93 | 0.13% |